相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current Clinical Applications of In Vivo Gene Therapy with AAVs
Jerry R. Mendell et al.
MOLECULAR THERAPY (2021)
Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics
Juergen Scharner et al.
MOLECULAR THERAPY (2021)
Fourth Boy Dies in Clinical Trial of Astellas' AT132
Alex Philippidis
HUMAN GENE THERAPY (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2021)
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue
Gretchen Thomsen et al.
NATURE MEDICINE (2021)
Delivery of oligonucleotide-based therapeutics: challenges and opportunities
Suzan M. Hammond et al.
EMBO MOLECULAR MEDICINE (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W. Day et al.
LANCET NEUROLOGY (2021)
Gene therapy for ALS: A review
Defne A. Amado et al.
MOLECULAR THERAPY (2021)
GENETIC THERAPIES FOR HUNTINGTON'S DISEASE FAIL IN CLINICAL TRIALS
Diana Kwon
NATURE (2021)
Double setback for ASO trials in Huntington disease
Katie Kingwell
NATURE REVIEWS DRUG DISCOVERY (2021)
Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS
Tetsuya Nagata et al.
NATURE BIOTECHNOLOGY (2021)
The current landscape of nucleic acid therapeutics
Jayesh A. Kulkarni et al.
NATURE NANOTECHNOLOGY (2021)
Gene Therapy for Neurodegenerative Disease: Clinical Potential and Directions
Xiaolin Zhu et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2021)
Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS
Tomoki Hirunagi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2021)
Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity
Wooi F. Lim et al.
SCIENCE ADVANCES (2021)
Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders
Ana C. Silva et al.
BRAIN (2020)
Clinical development on the frontier: gene therapy for duchenne muscular dystrophy
Damon R. Asher et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo
Masayuki Nakamori et al.
NATURE GENETICS (2020)
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy A Nonrandomized Controlled Trial
Jerry R. Mendell et al.
JAMA NEUROLOGY (2020)
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
Christian Mueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Timothy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy
Kenji Rowel Q. Lim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA)
Atsushi Hashizume et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Recent advances in molecular therapies for neurological disease: triplet repeat disorders
Pedro Gonzalez-Alegre
HUMAN MOLECULAR GENETICS (2019)
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease
Bryan Zeitler et al.
NATURE MEDICINE (2019)
A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system
Julia F. Alterman et al.
NATURE BIOTECHNOLOGY (2019)
Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease
Frederick J. Arnold et al.
NEUROTHERAPEUTICS (2019)
Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications
Sebastien Benizri et al.
BIOCONJUGATE CHEMISTRY (2019)
A multicenter, retrospective medical record review of X-linked myotubular myopathy: The recensus study
Alan H. Beggs et al.
MUSCLE & NERVE (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Polyglutamine Repeats in Neurodegenerative Diseases
Andrew P. Lieberman et al.
Annual Review of Pathology-Mechanisms of Disease (2018)
Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis
Zhang-Yu Zou et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
Hichem Tasfaout et al.
NATURE COMMUNICATIONS (2017)
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2017)
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia
Megan S. Keiser et al.
HUMAN MOLECULAR GENETICS (2016)
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Tsukasa Sugo et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice
Cy A. Stein
MOLECULAR THERAPY (2016)
MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy
Naemeh Pourshafie et al.
MOLECULAR THERAPY (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy
Kentaro Sahashi et al.
HUMAN MOLECULAR GENETICS (2015)
Muscle Expression of Mutant Androgen Receptor Accounts for Systemic and Motor Neuron Disease Phenotypes in Spinal and Bulbar Muscular Atrophy
Constanza J. Cortes et al.
NEURON (2014)
Oligonucleotide-based strategies to combat polyglutamine diseases
Agnieszka Fiszer et al.
NUCLEIC ACIDS RESEARCH (2014)
Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy
Andrew P. Lieberman et al.
CELL REPORTS (2014)
Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2
Yu Miyazaki et al.
NATURE MEDICINE (2012)
Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi Mechanism
Jiaxin Hu et al.
CHEMISTRY & BIOLOGY (2010)
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2010)
Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping
Chalermchai Mitrpant et al.
MOLECULAR THERAPY (2009)
Overexpression of IGF-1 in Muscle Attenuates Disease in a Mouse Model of Spinal and Bulbar Muscular Atrophy
Isabella Palazzolo et al.
NEURON (2009)
Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease
Douglas Ashley Monks et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation
M Eagle et al.
NEUROMUSCULAR DISORDERS (2002)
分享论文
